Fig. 4From: Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE studySustained reduction in OCS usage during benralizumab treatment. Daily OCS dosage (mg of prednisone equivalent), expressed as median (IQR), is shown at index date and after 48 and 96 weeks of treatment with benralizumabBack to article page